GUERBET |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.25 EUR | +2.62% |
|
+7.47% | +80.77% |
| Apr. 09 | Guerbet: CE certificate for a platform | CF |
| Apr. 09 | Intrasense: awarded CE certificate | CF |
| Sales 2024 * | 853M 913M | Sales 2025 * | 918M 983M | Capitalization | 443M 475M |
|---|---|---|---|---|---|
| Net income 2024 * | 28M 29.98M | Net income 2025 * | 39M 41.76M | EV / Sales 2024 * | 0.87 x |
| Net Debt 2024 * | 300M 322M | Net Debt 2025 * | 266M 284M | EV / Sales 2025 * | 0.77 x |
| P/E ratio 2024 * |
15.6
x | P/E ratio 2025 * |
11.2
x | Employees | 2,920 |
| Yield 2024 * |
1.65% | Yield 2025 * |
1.89% | Free-Float | 43.67% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.62% | ||
| 1 week | +3.37% | ||
| Current month | +7.31% | ||
| 1 month | +3.52% | ||
| 3 months | +88.50% | ||
| 6 months | +114.68% | ||
| Current year | +80.77% |
1 week
32.10
35.45
1 month
31.7535.55
Current year
17.0235.55
1 year
15.4835.55
3 years
15.2845.65
5 years
15.2856.40
10 years
15.2890.64
| Managers | Title | Age | Since |
|---|---|---|---|
David Hale
CEO | Chief Executive Officer | 55 | 18-01-31 |
Jérôme Estampes
DFI | Director of Finance/CFO | - | 19-03-31 |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thibault Viort
BRD | Director/Board Member | 51 | 17-05-18 |
Mark Fouquet
BRD | Director/Board Member | 64 | 14-05-22 |
| Director/Board Member | 62 | 13-05-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 35.25 | +2.62% | 11,790 |
| 24-04-22 | 34.35 | +1.63% | 13,517 |
| 24-04-19 | 33.8 | +2.27% | 15,974 |
| 24-04-18 | 33.05 | +1.07% | 17,710 |
| 24-04-17 | 32.7 | -0.30% | 15,425 |
Real-time Euronext Paris, April 23, 2024 at 11:36 am EDT
More quotes
Guerbet is a European leader in producing and selling contrast products for medical imaging. The group's products make it possible to visualize different organs and the lymphatic and vascular systems of the human body by making them opaque. Net sales break down by product family as follows:
- X-ray imaging products (55.4%);
- MRI products (32.7%);
- other (11.9%): contrast products for echography and nuclear medicine, fine chemicals products.
At the end of 2023 the group had 8 production sites located in France (4), the United States (2), Ireland and Brazil.
Europe accounts for 39.7% of net sales.
Calendar
2024-04-24
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
35.25
EUR
Average target price
38.63
EUR
Spread / Average Target
+9.60%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +80.77% | 460M | |
| -7.72% | 13.99B | |
| -40.07% | 2.71B | |
| -16.70% | 2.21B | |
| -12.18% | 1.43B | |
| -.--% | 1.12B | |
| +46.15% | 521M | |
| 0.00% | 210M | |
| +0.37% | 180M | |
| -.--% | 167M |
- Stock Market
- Equities
- GBT Stock
